Edgar Filing: Neos Therapeutics, Inc. - Form 4

Neos Therapeutics, Inc.

Form 4										
September 03	3, 2015									
FORM	14								PPROVAL	
-	UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549						N OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 chlications Filed pursuant to Section 166					GES IN BENEFICIAL OWNERSHIP OF SECURITIES 6(a) of the Securities Exchange Act of 1934, tility Holding Company Act of 1935 or Section				January 31, 2005 average Jrs per . 0.5	
may conti <i>See</i> Instru 1(b).	inue. Section 17(· · ·		•	ding Com t Company			on		
(Print or Type R	Responses)									
Eisenstadt Richard I Symbo			Symbol	Issuer Name and Ticker or Trading abol os Therapeutics, Inc. [NEOS]			5. Relationship of Reporting Person(s) to Issuer			
(1 +)				•			(Check all applicable)			
(M			3. Date of Earliest Transaction (Month/Day/Year) 09/01/2015			Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer				
				Amendment, Date Original Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
GRAND PR	AIRIE, TX 7505	50					Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative S	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3) 2. Transaction Date 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Instr. 8)	4. Securitie nAcquired (Disposed c (Instr. 3, 4	A) or of (D) and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	Ι
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

8 E S

(Instr. 3)	Price of Derivative Security		(Month/D	ay/Year)	(Instr. 8)	Acquired or Dispos (D) (Instr. 3, - and 5)	sed of				(
					Code V	(A)	(D) D E	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 25.5	09/01/2015			А	60,230		<u>(1)</u>	09/01/2025	Common Stock	60,230
Reporting Owners											
Reporting Owner Name / Address		Relationships									
C/O NEC 2940 N. I	Eisenstadt Richard I C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE, TX 75050			Director 10% Owner Officer Other Chief Financial Officer							
Signa	tures										
/s/ Benjamin Piper, attorney-in-fact		09/03/2	015								

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This stock option vests in equal yearly installments over a four-year period which began on September 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(